The exploration of using plasma biomarkers of p-tau217 and p-tau181 for screening Alzheimer’s disease in very elderly people
Plasma biomarkers p-tau181, p-tau217, and GFAP demonstrate clinical utility in distinguishing AD from normal cognition, suggesting that blood-based testing may serve as a feasible screening tool for early identification of AD in very elderly populations.
Authors
- Haiyan Wu
- Shouzi Zhang (ORCID: https://orcid.org/0000-0003-2260-9231)
- Lixin Liu (ORCID: https://orcid.org/0000-0003-4752-4787)
- Li Zhang (ORCID: https://orcid.org/0000-0002-8101-672X)
- Rui Li (ORCID: https://orcid.org/0000-0003-1044-1398)
- Xuelin He
- Tingyu Zhao (ORCID: https://orcid.org/0009-0000-5673-8328)
- Li Ma (ORCID: https://orcid.org/0000-0001-8455-6708)
Institutions
- Beijing Geriatric Hospital (CN)
- Institute of Psychology, Chinese Academy of Sciences (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fneur.2025.1668512
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China